

Eva Schrezenmeier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2402500/publications.pdf>

Version: 2024-02-01

42
papers

2,237
citations

430442

18
h-index

276539

41
g-index

51
all docs

51
docs citations

51
times ranked

4329
citing authors

#	ARTICLE	IF	CITATIONS
1	Altered increase in STAT1 expression and phosphorylation in severe COVID-19. <i>European Journal of Immunology</i> , 2022, 52, 138-148.	1.6	33
2	Evaluation of severity of delayed graft function in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 973-981.	0.4	8
3	Interstitial Nephritis: A Change in Diagnosis With Next-Generation Sequencing. <i>Kidney International Reports</i> , 2022, 7, 1128-1130.	0.4	2
4	B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. <i>Arthritis and Rheumatology</i> , 2022, 74, 934-947.	2.9	55
5	Authors' Reply: SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Should We Consider Intradermal Vaccination?. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 870-871.	3.0	0
6	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. <i>JCI Insight</i> , 2022, 7, .	2.3	62
7	Predictors of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Patients: Baseline Characteristics, Immunosuppression, and the Role of IMPDH Monitoring. <i>Journal of Clinical Medicine</i> , 2022, 11, 1697.	1.0	9
8	Poor Long-Term Renal Allograft Survival in Patients with Chronic Antibody-Mediated Rejection, Irrespective of Treatment—A Single Center Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 199.	1.0	4
9	B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients. <i>Frontiers in Immunology</i> , 2022, 13, 822885.	2.2	7
10	Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients. <i>Transplant International</i> , 2022, 35, 10109.	0.8	5
11	Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2565.	1.0	52
12	Poor Outcomes in Patients With Transplant Glomerulopathy Independent of Banff Categorization or Therapeutic Interventions. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	3
13	Plasmablast-like Phenotype Among Antigen-Experienced CXCR5 ⁺ CD19 ^{low} B Cells in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 1556-1568.	2.9	10
14	The relationship between proteinuria and allograft survival in patients with transplant glomerulopathy: a retrospective single-center cohort study. <i>Transplant International</i> , 2021, 34, 259-271.	0.8	4
15	What happens after graft loss? A large, long-term, single-center observation. <i>Transplant International</i> , 2021, 34, 732-742.	0.8	6
16	The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation. <i>Genetics in Medicine</i> , 2021, 23, 1219-1224.	1.1	28
17	Deep Phenotyping of CD11c ⁺ B Cells in Systemic Autoimmunity and Controls. <i>Frontiers in Immunology</i> , 2021, 12, 635615.	2.2	39
18	Exploring the Complexity of Death-Censored Kidney Allograft Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1513-1526.	3.0	67

#	ARTICLE	IF	CITATIONS
19	Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	4
20	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	5.6	223
21	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. <i>Frontiers in Immunology</i> , 2021, 12, 690698.	2.2	52
22	Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	212
23	Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2021, 10, 89.	1.0	5
24	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3027-3033.	3.0	82
25	First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine “ case report. <i>BMC Nephrology</i> , 2021, 22, 411.	0.8	22
26	<sc>EZH</sc>2 Inhibition in B Cell Subsets: Comment on the Article by Rohraff et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 371-373.	2.9	2
27	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 155-166.	3.5	952
28	Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 2136.	2.2	41
29	Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis. <i>Frontiers in Immunology</i> , 2019, 10, 29.	2.2	10
30	Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations. <i>Current Opinion in Rheumatology</i> , 2019, 31, 175-184.	2.0	20
31	TBC1D8B Mutations Implicate RAB11-Dependent Vesicular Trafficking in the Pathogenesis of Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2338-2353.	3.0	25
32	Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 53-58.	1.0	3
33	Assessment of the Kidney Donor Profile Index in a European cohort. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1465-1472.	0.4	36
34	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 741-758.	3.0	39
35	SaO014 USE OF A MOBILE APP TO IMPROVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE INTERVENTIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i321-i321.	0.4	1
36	FP713 DE NOVO MALIGNANCIES AFTER KIDNEY TRANSPLANTATION: A LONG-TERM OBSERVATIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i286-i286.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany. <i>Transplantation Proceedings</i> , 2017, 49, 2269-2273.	0.3	10
38	Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis. <i>American Journal of Transplantation</i> , 2017, 17, 819-823.	2.6	5
39	Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2143-2149.	0.4	21
40	The (pro)renin receptor mediates constitutive PLZF-independent pro-proliferative effects which are inhibited by bafilomycin but not genistein. <i>International Journal of Molecular Medicine</i> , 2014, 33, 795-808.	1.8	6
41	Moderate Correlations of in vitro versus in vivo Pharmacokinetics Questioning the Need of Early Microsomal Stability Testing. <i>Pharmacology</i> , 2012, 90, 307-315.	0.9	2
42	The (pro)renin receptor ((P)RR) can act as a repressor of Wnt signalling. <i>Biochemical Pharmacology</i> , 2012, 84, 1643-1650.	2.0	28